For Immediate Release

Chicago, IL – November 11, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Enzon (ENZN), Merck (MRK), OSI Pharmaceuticals (OSIP), Pfizer (PFE) and Bank of America Corporation (BAC).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

Enzon Beats, Announces Sell-off

Enzon (ENZN) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported revenues of $44.6 million, a decline of 9% compared to $48.8

...

Enzon (ENZN) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported revenues of $44.6 million, a decline of 9% compared to $48.8 million reported in the third quarter of 2008. Enzon records revenues from three sources -- products, royalties and contract manufacturing. The three segments recorded a decline of 1%, 6% and 56%, respectively, compared to the year-ago period. Enzon has four marketed products -- Oncaspar for the treatment of acute lymphoblastic leukemia (ALL); DepoCyt for lymphomatous meningitis; Abelcet for antifungal infection related to cancer and Adagen used to treat severe combined immunodeficiency disease (SCID), commonly known as the "bubble boy" disease. Apart from Oncaspar, whose sales remained unchanged from the year-ago period, the other three recorded a decline of 4%, 15% and 10%, ...

Micromet’s (MITI) third-quarter loss per share came in at 22 cents, well below the Zacks Consensus Estimate of 14 cents and a loss of 15 cents in the prior-year period. The company reported revenues of $4 million, compared to $7 million in the third quarter of 2008. Micromet records revenues primarily in the form of reimbursements of expenses incurred by the company under different collaborative agreements. We believe current investor focus is more on the developments of the company’s portfolio rather than the financials.

Operating expenses during the quarter increased 28% year over year to $17.13 million, primarily due to a 34% rise in R&D expenses. The increase in R&D expenses was driven by Micromet assuming full responsibility of the development of its lead candidate blinatumomab as per the company’s agreement with MedImmune.

As a reminder, earlier this month, Micromet had agreed to buy out MedImmune's option to reacquire the right

...

Hana Biosciences is a company that is clearly moving in the right direction. The company’s lead product candidate, Marquibo, has been developed to help all cancer patients battle the deadly disease and with news released today, the concept has a great deal of backing.

The young California Company announced there is a definite agreement in place with accredited investors to sell units consisting of common stocks and warrants which will result in total cash proceeds of $12.4 million the closing of which is expected to occur prior to October 9th with Piper Jaffray and Co. serving as exclusive place agent for the transaction.

The net proceeds of this offering will be used to support the completion of the pivotal Phase 2 clinical trial of Marquibo in adult patients with Philadelphia Chromosome negative acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in second relapse or who failed two prior lines of treatment. The

...

If there is one disease that has plagued our country and people across the globe, it would be cancer. Perhaps there is not a more tragic situation than when a child is stricken down with the deadly disease. One company is trying to make headway into Pediatric Cancer. That company is Hana Biosciences.

The San Francisco based Hana Biosciences is a biopharmaceutical company that has dedicated their resources and time to developing and commercializing new and differentiated cancer therapies with a plan to improve and enable standards of care amongst cancer patients. Hana took a major step towards achieving this goal with the announcement that they have entered into a Clinical Trial Agreement (CTA) with the Center for Cancer Research (CCR) at the National Cancer Institute for the co-development of Marquibo which is a vincristine sulfate liposomes injection in refractory pediatric cancer.

The CTA will occur over five-years

...

Genzyme Corp.’s (GENZ) Clolar could face a delay in receiving approval for an expanded indication. The drug will be coming up for review before the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on Sept 1 and questions have been raised regarding the lack of a randomized study supporting the application.

The company is seeking to get Clolar approved for the treatment of previously untreated adults aged 60 or older with acute myeloid leukemia (AML) who have at least one unfavorable prognostic risk factor. The company is seeking approval on the basis of a phase II study in which Clolar was evaluated in elderly patients with previously untreated AML and at least one other factor that gave them a poor prognosis. The study did not include any comparison with a placebo.

Clolar is currently approved for pediatric acute lymphoblastic leukemia (ALL) patients who have relapsed or refractory

...

DrStockPick.com Stock Report!

Monday August 3, 2009

**************************************************************

Acorn Energy, Inc. (Nasdaq: ACFN) today announced that it expects to report for the second quarter ended June 30, 2009, revenue of approximately $7.8 million, an increase of 116% from $3.6 million in the comparable quarter last year. In addition, the Company is estimating Q2 2009 gross profit of $3.5 million versus $1.0 million in Q1 2008, which represents the effects of increased revenues and an expected improvement in gross margins from 29% to 45%.

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has received Orphan Drug Designation from the European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103) for acute

...

Positive interim data from phase 2 clinical trials of lead drug candidate MT103Micromet, Inc. (MITI) announced yesterday that the German Multicenter ALL Study Group presented phase 2 clinical data of lead drug candidate BiTE antibody blinatumomab (MT103) at the 14th Congress of the European Hematology Association held recently in Berlin, Germany, showing a high response rate in acute lymphoblastic leukemia (ALL) patients with minimal residual disease (MRD).The patients included in this phase 2 clinical trial were in complete hematological remission following intense chemotherapy regimens, but had retained a detectable level of ALL cancer cells in their bone marrow, so called minimal residual disease (MRD). Various studies have confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD.The ALL interim data showed an MRD response rate above 80%, which significantly exceeded the rate which was considered ...

For Immediate Release

Chicago, IL - April 28, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Dynavax Technologies Corp. (DVAX),Skyworks Solutions, Inc. (SWKS), Wilmington Trust Corp. (WL), Micromet Inc. (MITI) and Embraer (ERJ).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Monday's Analyst Blog:

Dynavax Surge Not Warranted

In early morning trading, Dynavax Technologies Corp. (NASDAQ: DVAX) shares shot up dramatically (36%). However, we don't see a clear reason for that.

The surge may be related to two pieces of news: phase III Heplisav data and the swine

...

On Friday April 24, 2009, Micromet Inc. (MITI) held a briefing for investors and financial analysts in New York to provide an update on the company's drug development pipeline.A key highlight of the presentation was the announcement that a rapid path to market has been identified in acute lymphoblastic leukemia (ALL) for the company's lead drug candidate BiTE antibody blinatumomab (MT103) with a registration trial planned for 2010. This was in addition to a dose escalation study which is currently underway of blinatumomab for non Hodgkin's lymphoma, with final results expected to be reported at the American Society of Hematology meeting in December.MITI also provided an update on MT110, which is currently in a phase 1 dose-escalating clinical trial in patients with lung or gastrointestinal cancer. In addition, pre-clinical data for the company's EGFR BiTE Antibody, presented at the recent annual meeting of the ...